Comparison of bronchodilator administration with vibrating mesh nebulizer and standard jet nebulizer in the emergency department

Projects comparing bronchodilator response by aerosol devices in the ED are limited. Evidence suggests that the vibrating mesh nebulizer (VMN) provides 5-fold greater aerosol delivery to the lung as compared to a jet nebulizer (JN). The aim of this project was to evaluate a new nebulizer deployed in...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of emergency medicine 2018-04, Vol.36 (4), p.641-646
Main Authors: Dunne, Robert B., Shortt, Sandra
Format: Article
Language:English
Subjects:
Adapter
Aerosol
Aerosols
Age
Bronchodilators
Chronic obstructive pulmonary disease
Datasets
Demographics
Drug dosages
Efficiency
Electronic medical records
Emergency medical care
Emergency medical services
Heart rate
Jet nebulizer
Lungs
Medical electronics
Mesh
Patients
Pediatrics
Quality control
Statistical analysis
Vibrating mesh
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Projects comparing bronchodilator response by aerosol devices in the ED are limited. Evidence suggests that the vibrating mesh nebulizer (VMN) provides 5-fold greater aerosol delivery to the lung as compared to a jet nebulizer (JN). The aim of this project was to evaluate a new nebulizer deployed in an Emergency Department. A quality improvement evaluation using a prospectively identified data set from the electronic medical record comparing all ED patients receiving aerosolized bronchodilators with the JN during September 2015 to those receiving aerosolized bronchodilators with the VMN during October 2015. 1594 records were extracted, 879 patients received bronchodilators via JN and 715 patients via the VMN. Admission rates in the VMN group were 28.1% and in the JN group at 41.4%. The total albuterol dose administered was significantly lower in the VMN group compared to the JN (p5mg albuterol to control symptoms (85% of the VMN group received only 2.5mg) whereas dosing in the JN group was higher in some patients (with 47% receiving only 2.5mg). The use of VMN was also associated with a 13% (37min) reduction in median length of stay in the ED. The VMN was associated with fewer admissions to the hospital, shorter length of stay in the ED and a reduction in albuterol dose. The device type was a predictor of discharge, disposition and amount of drug used. Randomized controlled studies are needed to corroborate these findings.
ISSN:0735-6757
1532-8171
DOI:10.1016/j.ajem.2017.10.067